Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma

Summary

Lipoprotein(a) and total plasma homocysteine levels are now established as independent atherothrombogenic risk factors. A distinctive pathophysiological feature of lipoprotein(a) is its antifibrinolytic activity, an effect dependent on plasma concentration and high affinity for fibrin of its small size apo(a) component. A stimulating effect of homocysteine on purified lipoprotein(a) has been proposed. However, little is known about their specific interactions in human plasma. We demonstrate by immunochemical, ligand-binding and plasminogen activation studies, that homocysteine modifies the structure and function of lipoprotein(a) in human plasma; it reduces the apo(a)/apoB disulfide bond causing the appearance of free apo(a) with high affinity for fibrin that inhibits plasminogen binding and plasmin formation (r= −0.995, p=0.002). These effects were evident particularly in plasma samples containing lipoprotein(a) with low affinity for fibrin and more than 22 kringles apo(a) isoforms. In contrast, for plasmas containing high fibrin affinity lipoprotein(a) (less than 22 kringles apo[a] isoforms) no significant change neither in fibrin binding nor in plasmin formation was observed. Furthermore, isolated apo(a) recombinants (10 to 34 kringles) that have been shown to display size-independent high affinity for fibrin were not affected by homocysteine, thus confirming lipoprotein(a) as its main target. These results suggest that the pro-atherogenic role already conferred to lipoprotein(a) by small apo(a) isoforms may be extended to large apo(a) isoforms if released in plasma by homocysteine, as this mechanism reveals their high fibrin affinity. Lipoprotein(a) and homocysteine may therefore constitute, if acting in concert, a new risk factor for athero-thrombotic vascular disease.

Keywords

Homocysteine - lipoprotein(a) - apolipoprotein(a) - fibrinolytic activity - plasminogen

• References

• 1 Evans RW, Shaten BJ, Hempel JD. et al. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
• 2 Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
• 3 Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-43.
• 4 Foody JM, Milberg JA, Robinson K. et al. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493-9.
• 5 McLean JW, Tomlinson JE, Kuang WJ. et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
• 6 Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-56.
• 7 Plow EF, Freaney DE, Plescia J. et al. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-20.
• 8 Brunner C, Lobentanz EM, Petho-Schramm A. et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996; 271: 32403-10.
• 9 Hoover-Plow JL, Miles LA, Fless GM. et al. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry 1993; 32: 13681-7.
• 10 Ernst A, Helmhold M, Brunner C. et al. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32–36 of human apolipoprotein(a). J Biol Chem 1995; 270: 6227-34.
• 11 Edelstein C, Mandala M, Pfaffinger D. et al. Determinants of lipoprotein(a) assembly: a study of wildtype and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995; 34: 16483-92.
• 12 Eaton DL, Fless GM, Kohr WJ. et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A 1987; 84: 3224-8.
• 13 Hajjar KA, Gavish D, Breslow JL. et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
• 14 Boonmark NW, Lou XJ, Yang ZJ. et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997; 100: 558-64.
• 15 Hughes SD, Lou XJ, Ighani S. et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997; 100: 1493-500.
• 16 Miles LA, Fless GM, Scanu AM. et al. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 1995; 73: 458-65.
• 17 Rouy D, Grailhe P, Nigon F. et al. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991; 11: 629-38.
• 18 Hervio L, Durlach V, Girard-Globa A. et al. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995; 34: 13353-8.
• 19 Hervio L, Girard-Globa A, Durlach V. et al. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996; 26: 411-7.
• 20 Kronenberg F, Kronenberg MF, Kiechl S. et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100: 1154-60.
• 21 Kang C, Dominguez M, Loyau S. et al. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002; 22: 1232-8.
• 22 Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992; 89: 10193-7.
• 23 Angles-Cano E, Loyau S, Cardoso-Saldana G, Couderc R. et al. A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping. J Lipid Res 1999; 40: 354-9.
• 24 Sorell L, Rojas G, Rodriguez M. et al. A sandwich ELISA based on anti-apo(a) and anti-apo B monoclonal antibodies for lipoprotein(a) measurement. Clin Chim Acta 1995; 236: 59-70.
• 25 Tsurupa G, Ho-Tin-Noe B, Angles-Cano E. et al. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains. J Biol Chem 2003; 278: 37154-9.
• 26 Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-8.
• 27 Soulat T, Loyau S, Baudouin V. et al. Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol 2000; 20: 575-84.
• 28 de la Pena-Diaz A, Cardoso-Saldana G, Zamora-Gonzalez J. et al. Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. Eur J Clin Invest 2003; 33: 99-105.
• 29 Soulat T, Loyau S, Baudouin V. et al. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a). Thromb Haemost 1999; 82: 121-7.
• 30 Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 1991; 49: 1063-74.
• 31 Togawa T, Sengupta S, Chen H. et al. Mechanisms for the formation of protein-bound homocysteine in human plasma. Biochem Biophys Res Commun 2000; 277: 668-74.
• 32 Sengupta S, Chen H, Togawa T. et al. Albumin thiolate anion is an intermediate in the formation of albumin- S-S-homocysteine. J Biol Chem 2001; 276: 30111-7.
• 33 Ventura P, Panini R, Rosa MC. et al. Relevance of different apolipoprotein content in binding of homocysteine to plasma lipoproteins. Nutr Metab Cardiovasc Dis 2003; 13: 218-26.
• 34 Majors AK, Sengupta S, Willard B. et al. Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol 2002; 22: 1354-9.
• 35 Cauza E, Kletzmaier J, Bodlaj G. et al. Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003; 18: 1568-72.
• 36 Herrmann W, Quast S, Ellgass A. et al. An increased serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine. Nephron 2000; 85: 41-9.
• 37 Sengupta S, Wehbe C, Majors AK. et al. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 2001; 276: 46896-904.
• 38 Hajjar KA, Mauri L, Jacovina AT. et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-93.
• 39 Bescond A, Augier T, Chareyre C. et al. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999; 263: 498-503.
• 40 Undas A, Williams EB, Butenas S. et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276: 4389-97.
• 41 Hopkins PN, Wu LL, Hunt SC. et al. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2783-92.
• 42 Bostom AG, Shemin D, Lapane KL. et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91-101.